Most ypN + patients were diagnosed with HR+/HER2-breast cancer (n = 74, 64.3 %), 10.4 % (n = 12) with HR+/HER2+ subtype, two patients (1.7 %) with HR-/HER2+ subtype and 23.5 % (n = 27) with TN subtype (p-value <0.001). This evidence concerns the gene ERBB2 and breast cancer.